tldrdailynews.com logo

Personalised mRNA vaccine plus Keytruda halts melanoma relapse in trial

1 min read
Source: BBC
Personalised mRNA vaccine plus Keytruda halts melanoma relapse in trial
Photo: BBC
TL;DR

A phase 3 trial of a personalised mRNA vaccine (Intismeran) given with Keytruda after melanoma surgery extended disease-free time in over 1,000 high-risk patients. While the interim results are promising, they have not yet been peer-reviewed and regulatory approval is still required before NHS rollout.

Topics:businesshealth#health#immunotherapy#melanoma#mrna#personalised-medicine#vaccine
Share this article
  1. Vaccine breakthrough stops cancer returning in trial  BBC
  2. Moderna’s Shift to Cancer Company Lifts Stock Up 177%  The New York Times
  3. New mRNA vaccine could reduce the recurrence and spread of skin cancer  NPR
  4. Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar  CNBC
  5. Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today?  Yahoo Finance

Want the full story? Read the original reporting

Read on BBC